Search clinical trials for: BBI608

Total 107 results

Sumitomo Pharma America, Inc.

Completed

A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors

Cancer | Advanced Solid Tumors

United States
Sumitomo Pharma America, Inc.

Completed

A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
Sumitomo Pharma America, Inc.

Completed

A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma

Glioblastoma

United States, Canada
Sumitomo Pharma America, Inc.

Completed

A Study of BBI608 in Adult Patients With Advanced Malignancies

Cancer, Advanced Malignancies

Canada, United States
Sumitomo Pharma America, Inc.

Terminated

A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer (CanStem43L)

Carcinoma, Non-Small-Cell Lung

United States
Sumitomo Pharma America, Inc.

Completed

A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer (BRIGHTER)

Gastric Cancer | Gastroesophageal Junction Cancer

United States, Hungary, Spain, China, Brazil, France, Australia, Czechia, Germany, Israel, Canada, United Kingdom, Japan, Belgium, Romania, Italy, Poland, Lithuania, Korea, Republic of, Bulgaria, Estonia, Russian Federation
Sumitomo Pharma America, Inc.

Completed

A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

Cancer

United States, Canada
Sumitomo Pharma America, Inc.

Completed

A Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects

Healthy | ADME

United States
Sumitomo Pharma America, Inc.

Completed

A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer

Colorectal Cancer

United States
Sumitomo Pharma America, Inc.

Completed

A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers

Cancer

United States
NCIC Clinical Trials Group
Sumitomo Pharma Oncology, Inc.

Completed

BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma

Colorectal Carcinoma

Canada, Australia, Japan
Sumitomo Pharma America, Inc.

Completed

A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma (CanStem111P)

Carcinoma, Pancreatic Ductal

United States, France, Netherlands, Spain, Taiwan, China, Belgium, Korea, Republic of, Austria, Singapore, Japan, Italy, Germany, Portugal, Poland, Czechia, Australia, Canada, Russian Federation, Ukraine
BrodenBio Co., Ltd.

Recruiting

A Phase 1 Study of BB3008 in Participants With Advanced Solid Tumors

Advanced Solid Tumor

China
Sumitomo Pharma America, Inc.

Completed

A Study of BBI503 in Adult Patients With Advanced Solid Tumors

Cancer, Advanced Solid Tumors

United States, Canada
Innovent Biologics (Suzhou) Co. Ltd.

Completed

IBI308 in Subjects With Advanced/Metastatic Solid Malignancies

Advanced/Metastatic Solid Malignancies

United States
Blueberry Therapeutics
IQVIA Biotech

Completed

A Trial Involving Treatment of BB2603 in Subjects With Distal Subungual Onychomycosis of the Toenail

Fungal Infection | Distal Subungual Onychomycosis | Fungus, Nail

Poland, Germany, Czechia
Sumitomo Pharma America, Inc.

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy Volunteers

Drug-drug Interactions

United States
Shanghai Ninth People's Hospital Affiliated to...

Unknown

Sintilimab to Prevent High-risk Oral Premalignant Lesions Cancerization (STOP)

Precancerous Conditions | Oral Cavity Cancer | Mouth Neoplasm

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Efficacy and Safety of IBI310 Combined With Sintilimab in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer

Advanced Biliary Tract Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Sumitomo Pharma Co., Ltd.

Completed

A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

Japan
Beijing Tsinghua Chang Gung Hospital

Unknown

Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis

Hepatocellular Carcinoma | Portal Vein Tumor Thrombosis

China
Sumitomo Pharma America, Inc.

Completed

A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

Hematologic Malignancy

United States
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy

Advanced Cervical Cancer

China
Teva Pharmaceuticals USA

Completed

Cefadroxil 500 mg Capsules in Normal Healthy Non-Smoking Male and Female Subjects.

Healthy

United States, Canada
Harbin Medical University
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

Study of IBI343 in Subjects With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Fujian Haixi Pharmaceuticals Co., Ltd.

Recruiting

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

Solid Tumor

China
Sumitomo Pharma America, Inc.

Terminated

A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation

Cancer | Ovarian Cancer

United States
Sumitomo Pharma America, Inc.

Completed

A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer

Hepatocellular Carcinoma | Cholangiocarcinoma

Canada
Sumitomo Pharma America, Inc.

Terminated

A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumors

Canada
Sumitomo Pharma America, Inc.

Withdrawn

A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies

Renal Cell Carcinoma | Urothelial Carcinoma | Urologic Malignancies
Sichuan Cancer Hospital and Research Institute
Innovent Biologics, Inc.

Unknown

Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Thoracic Neoplasms | Non-small-cell Lung Cancer
Taizhou Hospital

Unknown

CT-Guided Adaptive Radiation Therapy Combine With Anti-PD-1 Antibody Adjuvant Immunotherapy for Thoracic Cancer Patients (CARTAI)

Thoracic Malignancies

China
SK Bioscience Co., Ltd.

Completed

Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age

Varicella

Philippines
SK Chemicals Co., Ltd.

Completed

Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over

Herpes Zoster

Korea, Republic of
SK Chemicals Co., Ltd.

Completed

Immunogenicity and Safety of Two Lots of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over

Herpes Zoster

Korea, Republic of
Mian XI

Recruiting

Combination of Sintilimab and Stereotactic Body Radiotherapy in Hepatocellular Carcinoma (ISBRT01) (ISBRT01)

Hepatocellular Carcinoma

China
SK Chemicals Co., Ltd.

Completed

The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of Age

Varicella

Philippines
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study

Metastatic Undifferentiated Pleomorphic Sarcoma | Recurrent Undifferentiated Pleomorphic Sarcoma | Locally Advanced Undifferentiated Pleomorphic Sarcoma | Unresectable Undifferentiated Pleomorphic Sarcoma

United States
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery

Acral Melanoma That Has Been Removed by Surgery

China
Peking Union Medical College Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Xinda Biopharmaceutical Group

Not yet recruiting

Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung
Innovent Biologics (Suzhou) Co. Ltd.
Innovent Biologics (USA), Inc.

Withdrawn

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma

United States, Germany, France, Australia, Spain, Switzerland, United Kingdom
Sumitomo Pharma Co., Ltd.

Completed

A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma

Non-Small Cell Lung Cancer | Malignant Pleural Mesothelioma

Japan
Innovent Biologics (Suzhou) Co. Ltd.

Completed

First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors

Cancer, Solid Tumor

China
Hospital Universitario La Paz
MED-EL Elektromedizinische Geräte GesmbH

Recruiting

Subjective and Audiological Benefit of BONEBRIDGE (BCI602) With Two Different Fitting Strategies

Quality of Life | Hearing Loss, Mixed | Bone Conduction Deafness

Spain
Sumitomo Pharma America, Inc.

Completed

A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CanStem303C)

Colorectal Cancer

United States, Canada, Spain, Australia, China, Hong Kong, Israel, Czechia, France, Japan, Belgium, Germany, Netherlands, Italy, Korea, Republic of, Singapore
Sun Yat-sen University
Fifth Affiliated Hospital, Sun Yat-Sen University; Ningbo Medical Center Lihuili...

Not yet recruiting

Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402) (HSBRT2402)

Hepatocellular Carcinoma

China
M.D. Anderson Cancer Center

Active, not recruiting

Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study

Locally Advanced Angiosarcoma | Metastatic Angiosarcoma | Recurrent Angiosarcoma

United States
Australasian Gastro-Intestinal Trials Group

Completed

Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer (MODULATE)

Colorectal Cancer Metastatic

Australia

Search clinical trials for: BBI608

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations